Tango Therapeutics
TNGXTNGX · Stock Price
Historical price data
Overview
Tango Therapeutics is a clinical-stage biotech focused on discovering and developing precision oncology medicines based on synthetic lethality. The company has built a robust pipeline with multiple clinical-stage assets, including PRMT5 and CoREST inhibitors, targeting cancers with specific genetic alterations like MTAP deletion and STK11 mutations. Its integrated discovery platform combines CRISPR-based functional genomics with patient-derived data to systematically identify novel drug targets, positioning it at the forefront of next-generation cancer therapeutics.
Technology Platform
An integrated synthetic lethality discovery platform combining CRISPR-based functional genomics, computational biology, and patient-derived data to systematically identify novel drug targets specific to cancer genetic vulnerabilities.
Pipeline
5| Drug | Indication | Stage | Watch |
|---|---|---|---|
| TNG908 | Locally Advanced Solid Tumor | Phase 1/2 | |
| TNG260 + Pembrolizumab | Non Small Cell Lung Cancer | Phase 1/2 | |
| TNG348 + Olaparib | Breast Cancer | Phase 1/2 | |
| S095035 + TNG462 | MTAP-deleted Solid Tumors | Phase 1/2 | |
| TNG462 + Pembrolizumab | Locally Advanced Solid Tumor | Phase 1/2 |
Opportunities
Risk Factors
Competitive Landscape
Tango competes in the precision oncology space with companies like IDEAYA Biosciences/GSK in PRMT5 inhibition and others in the USP1 and CoREST target areas. Its primary competitive edge is its integrated discovery platform, which systematically generates novel, biomarker-defined drug candidates, allowing for a potentially sustainable pipeline beyond its current assets.